论文部分内容阅读
目的:探讨静脉应用地尔硫卓治疗不稳定型心绞痛(UA)的临床疗效。方法:对42例硝酸酯类药物治疗效果不佳的UA病人静脉应用地尔硫卓,入院时心绞痛正在发作者给予首剂10 mg静脉注射后持续静脉滴注,心绞痛未发作者直接静脉滴注。初始地尔硫卓剂量为3mg/h,若心绞痛仍有发作,则递增剂量至12mg/h,心绞痛控制即按有效剂量持续静滴48 h。结果:42例UA病人中,地尔硫卓剂量为3mg/h有效者33例(78.6%),6mg/h有效者4例(9.5%),9mg/h有效者2例(4.7%),总有效率为92.8%。治疗过程中无严重不良事件发生。结论:静脉应用地尔硫卓治疗UA安全、有效,可作为治疗UA的一线药物。
Objective: To investigate the clinical efficacy of intravenous diltiazem in the treatment of unstable angina pectoris (UA). Methods: Diltiazem was intravenously administered to 42 UA patients with poor response to nitrates, and angina pectoris was admitted to the hospital with intravenous infusion of the first dose of 10 mg intravenously. The patients without angina pectoris were directly injected intravenously. Initially diltiazem dose of 3mg / h, if the angina pectoris still seizures, the escalating dose to 12mg / h, angina pectoris that the effective dose of intravenous infusion of 48h. Results: Of the 42 UA patients, 33 (78.6%) patients were treated with diltiazem at 3 mg / h, 4 (9.5%) at 6 mg / h and 2 at 4.7 mg 92.8%. No serious adverse events occurred during the treatment. Conclusion: Intravenous diltiazem in the treatment of UA is safe and effective and can be used as first-line treatment for UA.